|
May 9
|
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
|
|
May 7
|
Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 7
|
Castle Biosciences Celebrates Skin Cancer Awareness Month
|
|
May 6
|
Q1 2025 Castle Biosciences Inc Earnings Call
|
|
May 6
|
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
|
|
May 5
|
Castle Biosciences Reports First Quarter 2025 Results
|
|
May 5
|
Castle Biosciences to Acquire Previse
|
|
May 2
|
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
|
|
Feb 24
|
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
|
|
Feb 20
|
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Feb 20
|
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
|
|
Feb 12
|
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
|
|
Feb 12
|
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
|
|
Feb 12
|
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
|
|
Feb 12
|
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
|
|
Jan 3
|
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
|
Jan 3
|
Neumora Stock Hits Record Low on Depression Drug Study Failure
|
|
Jan 2
|
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
|